CompletedInterventionalPhase 3Last updated Jun 21, 2013

A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g

Overview

ClinicalTrials.gov ID: NCT00109252
Lead Sponsor: Genentech, Inc.INDUSTRY
Brief Summary: This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Jan 2002
Primary Completion Date: No data available
Completion Date: Apr 2003Actual

Study Record Dates

First Submitted: Apr 26, 2005
First Submitted that Met QC Criteria: Apr 25, 2005
First Posted: Apr 26, 2005Estimated
Last Update Submitted that Met QC Criteria: Jun 19, 2013
Last Update Posted: Jun 21, 2013Estimated
Last Verified: Jun 2013

NCT00096603Completed

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

NCT00109317Completed

A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT00336973Completed

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

NCT00096980Completed

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

NCT00115076Completed

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT00287118Completed

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis